文献速递肿瘤 PET/CT放射性药物与辐射防护

[18F]AmBF3-TATE的药代动力学、辐射剂量学、急性毒性与自动化合成

Pharmacokinetics, radiation dosimetry, acute toxicity and automated synthesis of [18F]AmBF3-TATE.
PubMed 文献 · EJNMMI Res · 2020-03-19

本研究以良好实验室规范(GLP)标准评估生长抑素受体2(SSTR2)激动剂[18F]AmBF3-TATE的药代动力学、辐射剂量学与急性毒性,并在Trasis AllinOne模块上实现自动化合成。小鼠生物分布显示其经肾与肝胆途径清除,胰腺、胃、肺特异性摄取最高,预注射[19F]AmBF3-TATE可显著降低胰腺摄取。OLINDA推算成人膀胱、胰腺、肺剂量最高;大鼠14天观察未见受试物相关效应;自动化合成产额15.6 ± 4.59 GBq、摩尔活度435 ± 162 GBq/μmol、放射化学纯度98.0 ± 1.73%。

要点

  • 小鼠1 h p.i.胰腺、胃、肺特异性摄取最高,预注射[19F]AmBF3-TATE后胰腺摄取显著降低。
  • OLINDA推算成人膀胱、胰腺、肺受照剂量最高。
  • 大鼠在0.742 mg/kg [19F]AmBF3-TATE下14天观察未见受试物相关效应。

核心结论

  • [18F]AmBF3-TATE特异性结合SSTR2。
  • 在1000倍临床剂量下,[19F]AmBF3-TATE耐受良好,无治疗相关不良效应。

研究设计与样本

  • ICR小鼠静脉注射0.8-2.0 MBq [18F]AmBF3-TATE,一组于给药前30 min预注射100 μg [19F]AmBF3-TATE以评估摄取特异性,注射后0.5、1、2、4 h处死。
  • 基于生物分布数据用OLINDA软件的小鼠与人体模计算剂量学。
  • Sprague-Dawley大鼠以0.742 mg/kg [19F]AmBF3-TATE评估急性毒性,观察/恢复期14天。
  • [18F]AmBF3-TATE在Trasis AllinOne合成模块上实现自动化生产。

主要发现

  • [18F]AmBF3-TATE经肾与肝胆途径清除。
  • 1 h p.i.胰腺摄取为雌性15.7 ± 3.72 %ID/g、雄性14.3 ± 1.61 %ID/g,胃为雌性15.3 ± 3.63 %ID/g、雄性19.0 ± 3.49 %ID/g,肺为雌性9.26 ± 2.24 %ID/g、雄性6.17 ± 6.04 %ID/g。
  • 预注射[19F]AmBF3-TATE使1 h p.i.胰腺摄取显著降低至雌性0.13 ± 0.03 %ID/g、雄性0.18 ± 0.09 %ID/g。
  • 推算至平均成人,膀胱0.027-0.030 mGy/MBq、胰腺0.018-0.028 mGy/MBq、肺0.006-0.013 mGy/MBq预计受照剂量最高。
  • 急性毒性评估中临床观察、体重、摄食量、临床病理、大体病理与组织病理学均未观察到受试物相关效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: [18F]AmBF3-TATE is a somatostatin agonist that selectively binds to somatostatin receptor subtype 2 (SSTR2). For clinical translation, pharmacokinetics, radiation dosimetry, and acute toxicity of [18F]AmBF3-TATE were assessed with good laboratory practice (GLP) standards. METHODS: ICR mice were intravenously administered 0.8-2.0 MBq of [18F]AmBF3-TATE, with one group pre-injected with 100 μg of [19F]AmBF3-TATE 30 min before radiopharmaceutical administration to assess uptake specificity. The mice were euthanized at 0.5, 1, 2, or 4 h post-injection (p.i.). Blood and tissues were collected, weighed, and counted on a gamma counter to determine percentage injected dose per gram (%ID/g). Dosimetry was calculated based on biodistribution data using the mouse and human phantoms included in OLINDA. Acute toxicity was assessed in Sprague-Dawley rats at the dose of 0.742 mg/kg [19F]AmBF3-TATE, with a 14-day observation/recovery period. Blood chemistry parameters, gross, and histopathology were evaluated. Body weight change and food consumption were monitored. The production of [18F]AmBF3-TATE was automated on a Trasis AllinOne synthesis module. RESULTS: [18F]AmBF3-TATE was cleared through the renal and hepatobiliary pathway. At 1 h p.i., the pancreas (F, 15.7 ± 3.72 and M 14.3 ± 1.61 %ID/g), stomach (F, 15.3 ± 3.63 and M, 19.0 ± 3.49 %ID/g), and lungs (F, 9.26 ± 2.24 and M, 6.17 ± 6.04 %ID/g) were the organs with the highest specific uptake. Pre-injection with [19F]AmBF3-TATE significantly reduced pancreatic uptake (F, 0.13 ± 0.03 and M, 0.18 ± 0.09 %ID/g) at 1 h p.i. For dosimetry extrapolated to the average adult human, the bladder (0.027-0.030 mGy/MBq), pancreas (0.018-0.028 mGy/MBq), and lungs (0.006-0.013 mGy/MBq) are expected to receive the highest doses. No test-item related effects were observed upon evaluation of clinical observations, body weights, food consumption, clinical pathology, gross pathology, and histopathology for acute toxicity. [18F]AmBF3-TATE was produced at activity yields of 15.6 ± 4.59 GBq, average molar activity of 435 ± 162 GBq/μmol, and radiochemical purity of 98.0 ± 1.73% with the automated synthesizer. CONCLUSION: [18F]AmBF3-TATE binds specifically to SSTR2. At 1000× clinical dose, [19F]AmBF3-TATE was well tolerated with no treatment-related adverse effects.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Lau J, Pan J, Rousseau E, et al. Pharmacokinetics, radiation dosimetry, acute toxicity and automated synthesis of [18F]AmBF3-TATE. EJNMMI Res. 2020. PMID: 32189151. doi:10.1186/s13550-020-0611-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。